S&P 500   3,359.06 (-0.62%)
DOW   29,151.16 (-0.84%)
QQQ   233.64 (-0.43%)
AAPL   316.88 (-2.48%)
FB   216.41 (+1.04%)
MSFT   186.43 (+0.58%)
GOOGL   1,517.94 (-0.05%)
AMZN   2,134.80 (+0.00%)
CGC   22.22 (+0.41%)
BABA   217.98 (-0.75%)
MU   57.44 (-1.81%)
TSLA   844.15 (+5.51%)
AMD   56.81 (+2.71%)
T   38.14 (-0.29%)
ACB   1.60 (+0.63%)
F   8.06 (-0.49%)
PRI   135.53 (-0.96%)
BAC   34.13 (-2.07%)
DIS   138.46 (-0.77%)
GILD   67.22 (-0.50%)
S&P 500   3,359.06 (-0.62%)
DOW   29,151.16 (-0.84%)
QQQ   233.64 (-0.43%)
AAPL   316.88 (-2.48%)
FB   216.41 (+1.04%)
MSFT   186.43 (+0.58%)
GOOGL   1,517.94 (-0.05%)
AMZN   2,134.80 (+0.00%)
CGC   22.22 (+0.41%)
BABA   217.98 (-0.75%)
MU   57.44 (-1.81%)
TSLA   844.15 (+5.51%)
AMD   56.81 (+2.71%)
T   38.14 (-0.29%)
ACB   1.60 (+0.63%)
F   8.06 (-0.49%)
PRI   135.53 (-0.96%)
BAC   34.13 (-2.07%)
DIS   138.46 (-0.77%)
GILD   67.22 (-0.50%)
S&P 500   3,359.06 (-0.62%)
DOW   29,151.16 (-0.84%)
QQQ   233.64 (-0.43%)
AAPL   316.88 (-2.48%)
FB   216.41 (+1.04%)
MSFT   186.43 (+0.58%)
GOOGL   1,517.94 (-0.05%)
AMZN   2,134.80 (+0.00%)
CGC   22.22 (+0.41%)
BABA   217.98 (-0.75%)
MU   57.44 (-1.81%)
TSLA   844.15 (+5.51%)
AMD   56.81 (+2.71%)
T   38.14 (-0.29%)
ACB   1.60 (+0.63%)
F   8.06 (-0.49%)
PRI   135.53 (-0.96%)
BAC   34.13 (-2.07%)
DIS   138.46 (-0.77%)
GILD   67.22 (-0.50%)
S&P 500   3,359.06 (-0.62%)
DOW   29,151.16 (-0.84%)
QQQ   233.64 (-0.43%)
AAPL   316.88 (-2.48%)
FB   216.41 (+1.04%)
MSFT   186.43 (+0.58%)
GOOGL   1,517.94 (-0.05%)
AMZN   2,134.80 (+0.00%)
CGC   22.22 (+0.41%)
BABA   217.98 (-0.75%)
MU   57.44 (-1.81%)
TSLA   844.15 (+5.51%)
AMD   56.81 (+2.71%)
T   38.14 (-0.29%)
ACB   1.60 (+0.63%)
F   8.06 (-0.49%)
PRI   135.53 (-0.96%)
BAC   34.13 (-2.07%)
DIS   138.46 (-0.77%)
GILD   67.22 (-0.50%)
Log in

NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News

$28.04
0.00 (0.00 %)
(As of 11/12/2019)
Today's Range
$28.04
Now: $28.04
$28.04
50-Day Range
$28.04
MA: $28.04
$28.04
52-Week Range
$5.62
Now: $28.04
$28.54
Volume35,036 shs
Average Volume499,313 shs
Market Capitalization$807.55 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.35 million
Book Value$2.71 per share

Profitability

Net Income$-72,280,000.00
Net Margins-544.09%

Miscellaneous

Employees115
Market Cap$807.55 million
Next Earnings DateN/A
OptionableOptionable

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.


Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its earnings results on Tuesday, August, 6th. The company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.03. The firm had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History.

What price target have analysts set for DOVA?

6 Wall Street analysts have issued 1 year price objectives for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they expect Dova Pharmaceuticals' stock price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

What is the consensus analysts' recommendation for Dova Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

Has Dova Pharmaceuticals been receiving favorable news coverage?

News articles about DOVA stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Dova Pharmaceuticals.

Who are some of Dova Pharmaceuticals' key competitors?

What other stocks do shareholders of Dova Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), TESARO (TSRO), TherapeuticsMD (TXMD), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Immunomedics (IMMU).

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:
  • Dr. David S. Zaccardelli, Pres & CEO (Age 54)
  • Mr. Mark W. Hahn, CFO & Sec. (Age 56)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
  • Mr. Jason Levine, VP of Marketing
  • Mr. Ilija Zlatar, Head of U.S. Sales

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

How do I buy shares of Dova Pharmaceuticals?

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $28.04.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

What is Dova Pharmaceuticals' official website?

The official website for Dova Pharmaceuticals is http://www.dova.com/.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]


MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel